Qualigen Therapeutics(QLGN) - 2020 Q1 - Quarterly Report

Financial Performance - The company has not generated any revenue from product sales since inception and relies on equity offerings and other financing methods for operational activities[89]. - The company has not generated any product revenues and has not achieved profitable operations as of March 31, 2020[119]. - Future revenue generation is uncertain and contingent upon successful development and marketing approval of product candidates, which may take several years[131]. - As of March 31, 2020, the company had an accumulated deficit of approximately $82.0 million, with net working capital of approximately $4.5 million and cash and cash equivalents of approximately $6.0 million[118][125]. - Net cash used in operating activities for the three months ended March 31, 2020, was approximately $1.2 million, reflecting a net loss of approximately $1.7 million[121]. - Net cash provided by financing activities for the three months ended March 31, 2020, was approximately $5.4 million, including proceeds from the issuance of shares under the ATM Agreement[123]. - The company sold approximately 16.8 million shares of common stock under the ATM Agreement for net proceeds of approximately $4.3 million after commissions and expenses[130]. Research and Development - The company has incurred approximately $39.6 million in research and development expenses since inception through March 31, 2020[90]. - The Phase 3 clinical trial of RP-G28 failed to demonstrate statistical significance in its primary and secondary endpoints, leading to the suspension of its development[84]. - The company inactivated the IND application for RP-G28 on February 21, 2020, due to the decision not to proceed with its clinical development[85]. - Research and development expenses decreased by approximately $3.6 million, or 100%, for the three months ended March 31, 2020, compared to the same period in 2019, primarily due to the suspension of development efforts for RP-G29 after a failed Phase 3 clinical trial[113]. - The company anticipates needing to raise additional capital for future development activities and commercialization efforts[89]. General and Administrative Expenses - General and administrative expenses are expected to increase in connection with the proposed merger, including fees for outside consultants and legal services[94]. - General and administrative expenses increased by approximately $1.1 million, or 92%, during the three months ended March 31, 2020, mainly due to increased legal and accounting fees related to a potential merger with Qualigen[115]. Strategic Initiatives - The company has engaged A.G.P./Alliance Global Partners as a financial advisor to explore strategic alternatives, including potential mergers or acquisitions[86]. - The merger agreement with Qualigen, Inc. was entered into on January 15, 2020, with Qualigen becoming a wholly-owned subsidiary of the company[87]. Other Income - Other income increased by approximately $0.5 million, or 668%, during the three months ended March 31, 2020, primarily due to successful renegotiation of outstanding trade payables[117]. Patent Costs - Patent costs decreased by approximately $45,000, or 92%, for the three months ended March 31, 2020, due to a significant reduction in the patent filing strategy[114].